Trial :

Flu and RSV Vaccine Study

Age :

Aged 65+

Trial length :

2 study visits

Info :

1 follow up visit

Respiratory syncytial virus (RSV) is a leading cause of respiratory illness in adults (second to the flu) with no specific prevention and treatment options. While RSV can infect anyone, for some people, especially babies, older adults, and those with heart or lung problems or weakened immune systems, symptoms can be more severe.  Around the world, there is an urgent need for a vaccine that can prevent RSV. That’s why Pfizer is conducting the C3671006 investigational RSV vaccine and flu vaccine study. Pfizer is committed to developing a safe and effective vaccine to prevent RSV or make it less severe, with a special focus on protecting infants and older adults.

We are enrolling healthy males and females who (among other things):

  • Are 65 years of age and older
  • Are generally in good health but may have stable chronic medical conditions
  • Do not have a history of severe side effects from or allergic reactions to vaccines
  • Have not had a flu vaccine in the last six months

The C3671006 RSV vaccine study will last about two months during which participants will be asked to attend about three study visits. This includes two vaccination visits and a follow-up visit. All eligible participants in the study will receive the investigational RSV vaccine and the seasonal flu vaccine.

If you meet the criteria for this study and would like more information, please register using the button below or call our Recruitment Team on 1800 727 874.